Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11617MR)

This product GTTS-WQ11617MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11617MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14242MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ11924MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ1015MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ15422MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ12357MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ15487MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ8414MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ6107MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.